2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5634 SWOG S2504: A randomized Phase III study of pirtobrutinib plus R-CHOP versus R-CHOP for participants with previously untreated Richter transformation (pirAMID Study)

Mazyar Shadman, MD, MPH, Othus Megan, PhD2, Anna Moseley, MS3, Farrukh T Awan, M.D.M.S.,M.B.A.4, Michael J. Thirman, MD5, Sonali Smith, MD, FASCO6, Jennifer E. Amengual, MD7, Anjali Sunder Advani, MD8, Harry P. Erba, MD9, Alexey V. Danilov, MD, PhD10, Deborah Stephens, DO11
1 Fred Hutchinson Cancer Center/University of Washington, Seattle, United States
2 Fred Hutchinson Cancer Center/University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center/University of Washington, Seattle, Washington, United States, Fred Hutchinson Cancer Center/University of Washington, Seattle, Washington, United States
4 UT Southwestern Medical Center, Dallas, United States
5 University of Chicago, Chicago, United States
6 University of Chicago, Chicago, United States
7 Columbia University, New York, United States
8 Cleveland Clinic, Cleveland, United States
9 Duke University, Durham, United States
10 City of Hope, Duarte, United States
11 University of North Carolina, Chapel Hill, United States

Background: Richter transformation (RT), the progression of chronic lymphocytic leukemia (CLL) to an aggressive lymphoma [most commonly diffuse large B-cell lymphoma (DLBCL)], occurs in ~5-10% of CLL patients and carries a median overall survival (OS) <12 months despite modern chemoimmunotherapy. R-CHOP remains the most commonly used first-line regimen for RT, but its efficacy is limited. No targeted therapies are currently approved for this indication. Pirtobrutinib, a highly selective, non-covalent, reversible Bruton tyrosine kinase inhibitor (BTKi) has shown promising monotherapy efficacy and a favorable, manageable safety profile in heavily pretreated RT patients, including durable responses without observed treatment-related mortality (Wierda 2024). Given the established feasibility of combining BTKis with R-CHOP in aggressive B-cell lymphomas (e.g., ibrutinib plus R-CHOP in DLBCL, and the ongoing STELLAR trial of acalabrutinib plus R-CHOP in RT), there is rationale to evaluate whether adding pirtobrutinib to R-CHOP improves outcomes with limited additional toxicity in previously untreated RT.

Study Design and Methods: S2504 (NCT07220187) is a randomized, open-label, phase III trial conducted through the US NCTN, led by SWOG for patients with treatment-naïve RT to DLBCL. The study begins with two parallel safety run-in cohorts (up to 6 evaluable participants each) stratified by age (<75 vs. ≥75 years), since patients under 75 receive standard R-CHOP while those 75 and older receive the attenuated R-mini-CHOP backbone. Each run-in cohort receives pirtobrutinib plus the age-appropriate chemoimmunotherapy backbone; randomization opens for an age cohort only if 0 or 1 of 6 participants experience a ≥10-day R-CHOP/R-mini-CHOP delay attributable to pirtobrutinib and 0 participants experience a related grade 5 event. Following successful run-in, eligible participants are randomized 1:1 to pirtobrutinib plus R-CHOP (or R-mini-CHOP for those ≥75) followed by pirtobrutinib maintenance versus R-CHOP (or R-mini-CHOP) alone, stratified by prior progressive disease on covalent BTKi (yes/no) and age (<75, ≥ 75). Key eligibility criteria include previously untreated RT confirmed per protocol diagnostic criteria, adequate organ function, and ECOG performance status consistent with ability to tolerate chemoimmunotherapy, with concurrent BTKi use disallowed on the control arm. The trial employs the Lugano Classification for staging and response assessment. The primary objective is to compare progression-free survival (PFS) between arms, followed by a hierarchical comparison of OS if PFS crosses its efficacy boundary. The design assumes exponential survival and is powered to detect an improvement in median PFS from 10 to 20 months (HR 0.5) and an improvement in median OS from 15 to 30 months (HR 0.5). Secondary and translational objectives include overall response rate, associations between high-risk Richter-associated mutations (TP53, CDKN2A, or MYC pathway alterations) and outcomes, mutational landscape characterization via targeted NGS and whole-exome sequencing, minimal residual disease assessment, and patient-reported symptom burden using PRO-CTCAE and FACIT-GP5 instruments. The randomized phase requires 80 eligible participants, with up to 12 additional participants for the safety run-ins; accounting for a 10% ineligibility/non-evaluability rate, total planned enrollment is up to 102 participants. The final PFS analysis will occur after 75 PFS events across both arms, with two interim futility analyses at approximately 50% and 75% of expected events; the design provides 90% power for PFS and 80-89% power for OS depending on the hierarchical testing strategy, at a one-sided alpha of 5%. A Data and Safety Monitoring Committee oversees the trial, including monitoring boundaries for treatment-related mortality and monitoring of BTKi use on the control arm.  The study activated on June 1, 2026 and can be opened at any cooperative group site in the United States.

Mazyar Shadman, MD, MPH: Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current equity holder in private company; Janssen - Research Funding; AstraZeneca - Research Funding; Sana Biotechnology - Research Funding; Nurix - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Morphosys/Incyte - Research Funding; AbbVie - Research Funding; Beigene - Research Funding; Genmab - Research Funding; Incyte - Research Funding; Vincerx - Research Funding; Mustang Bio - Research Funding; Merck - Research Funding; AstraZeneca - Research Funding; BeOne Medicines - Research Funding; Legend Bio - Research Funding; AbbVie - Research Funding; Genetech - Research Funding; Genmab - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Ascentage Pharma - Consultancy (Includes expert testimony); Mustang Bio - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Genetech - Consultancy (Includes expert testimony); Pierre Fabre - Consultancy (Includes expert testimony); Legend Bio - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Kite, A Gilead company - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Morphosys/Incyte - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); Fate therapeutics - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)